Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B-cell Malignancies.
Saved in:
| Title: | Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B-cell Malignancies. |
|---|---|
| Authors: | Coffey GP; Biology and Pharmacology, Portola Pharmaceuticals, Inc., South San Francisco, California. gcoffey@portola.com., Feng J; Research and Development, Portola Pharmaceuticals, Inc., South San Francisco, California., Betz A; Research and Development, Portola Pharmaceuticals, Inc., South San Francisco, California., Pandey A; Medicinal Chemistry and Chemical Development, Portola Pharmaceuticals, Inc., South San Francisco, California., Birrell M; Corporate Development, Portola Pharmaceuticals, Inc., South San Francisco, California., Leeds JM; Drug Metabolism and Pharmacokinetics, Portola Pharmaceuticals, Inc., South San Francisco, California., Der K; Pharmacokinetics, Portola Pharmaceuticals, Inc., South San Francisco, California., Kadri S; Department of Pathology, University of Chicago, Chicago, Illinois., Lu P; Department of Pathology, University of Chicago, Chicago, Illinois., Segal J; Department of Pathology, University of Chicago, Chicago, Illinois., Wang YL; Department of Pathology, University of Chicago, Chicago, Illinois., Michelson G; Clinical Development, Portola Pharmaceuticals, Inc., South San Francisco, California., Curnutte JT; Research and Development, Portola Pharmaceuticals, Inc., South San Francisco, California., Conley PB; Biology, Portola Pharmaceuticals, Inc., South San Francisco, California. |
| Source: | Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2019 Feb 15; Vol. 25 (4), pp. 1174-1184. Date of Electronic Publication: 2018 Oct 17. |
| Publication Type: | Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
